BackEntera Bio Overview

Entera Bio Receivables

Entera Bio's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-126000.00 vs prior year quarter

Peer average

Loading

Entera Bio Receivables History

Loading

Entera Bio vs. peers: Receivables Comparison

Loading

Entera Bio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Entera Bio (ENTX) FAQ

As of the most recent data (March 2026), ENTX shows a receivables of $0. That compares with $130K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ENTX's receivables is now $0 (was $130K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Entera Bio is outperforming or lagging.

Tracking ENTX's receivables over time shows whether Entera Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $130K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Entera Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Entera Bio's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.